| pubmed-article:12719710 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0664336 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0028948 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:12719710 | lifeskim:mentions | umls-concept:C1514485 | lld:lifeskim |
| pubmed-article:12719710 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12719710 | pubmed:dateCreated | 2003-4-29 | lld:pubmed |
| pubmed-article:12719710 | pubmed:abstractText | Survivin is expressed in most cancers but is undetectable in differentiated adult cells, and plays an important role both in the suppression of apoptosis and mitotic spindle checkpoint; thus it has attracted great interest as a potential drug target. In this study, we investigated the antigene and antiproliferative effects of triplex-forming oligodeoxynucleotides (TFO) targeting survivin in human lung carcinoma A549 cells. Survivin-specific TFOs form stable triplexes under physiological conditions as tested by electrophoretic mobility shift assays. Treatment of A549 cells with survivin-specific but not control TFOs at a concentration of 400 nM in the presence of uptake-enhancing liposome significantly reduced survivin protein level, inhibited cell proliferation, and induced cell apoptosis as demonstrated by immunoblot, cell number counting, and Annexin V-staining. Moreover, we found that the triplex-forming potential of TFOs measured in vitro does not necessarily correlate with the ability of TFOs to affect expression of a targeted gene in vivo. Our results indicate that targeting survivin is a promising alternative strategy for the development of novel anticancer therapeutics. | lld:pubmed |
| pubmed-article:12719710 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12719710 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12719710 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12719710 | pubmed:month | May | lld:pubmed |
| pubmed-article:12719710 | pubmed:issn | 0929-1903 | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:ReskeSven NSN | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:BuckAndreasA | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:PolatBülentB | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:ShenChangxian... | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:Schmid-Kotsas... | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:BachemMaxM | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:MatuschekChri... | lld:pubmed |
| pubmed-article:12719710 | pubmed:author | pubmed-author:GrossHans-Jue... | lld:pubmed |
| pubmed-article:12719710 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12719710 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:12719710 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12719710 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12719710 | pubmed:pagination | 403-10 | lld:pubmed |
| pubmed-article:12719710 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:meshHeading | pubmed-meshheading:12719710... | lld:pubmed |
| pubmed-article:12719710 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12719710 | pubmed:articleTitle | Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. | lld:pubmed |
| pubmed-article:12719710 | pubmed:affiliation | Department of Nuclear Medicine University of Ulm, Ulm, Germany. | lld:pubmed |
| pubmed-article:12719710 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12719710 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12719710 | lld:pubmed |
